Therapeutically, these insights are relevant, as IL-6 and IL-11 signaling have emerged as promising targets for metabolic-inflammatory liver disease, with IL-11 shown to potentiate matrix deposition and hepatocyte dysfunction under metabolic stress [35]. This evidence concerns the gene IL11 and liver disorder.